+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chemotherapy Induced Neutropenia Market by Product Type (Eflapegrastim, Filgrastim, Lipegfilgrastim), Therapy (Prophylaxis, Treatment), Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2030- Product Image
Chemotherapy Induced Neutropenia Market by Product Type (Eflapegrastim, Filgrastim, Lipegfilgrastim), Therapy (Prophylaxis, Treatment), Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2030- Product Image
Sale

Chemotherapy Induced Neutropenia Market by Product Type (Eflapegrastim, Filgrastim, Lipegfilgrastim), Therapy (Prophylaxis, Treatment), Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011313
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Chemotherapy induced neutropenia is a crucial focus in the evolving oncology landscape, demanding sophisticated management strategies to ensure patient safety and minimize treatment interruptions. Forward-thinking organizations must navigate a complex mix of therapeutic advancements, regulatory adjustments, and evolving clinical workflows to drive improved outcomes and maintain competitive positioning in this dynamic market.

Market Snapshot: Chemotherapy Induced Neutropenia Market Overview

The Chemotherapy Induced Neutropenia Market grew from USD 7.77 billion in 2024 to USD 8.10 billion in 2025. It is expected to continue growing at a CAGR of 4.06%, reaching USD 9.87 billion by 2030. Market growth reflects increased adoption of advanced granulocyte colony-stimulating factors, biosimilar alternatives, and digital patient management platforms. Shifting payer requirements, regulatory changes, and global supply chain considerations continue to shape the competitive environment, creating both opportunities and challenges for established players and emerging entrants.

Scope & Segmentation

This comprehensive report provides deep analysis across the entire chemotherapy induced neutropenia therapeutic spectrum. The segmentation framework enables actionable insights into patient-centric strategies, formulation innovations, and regional dynamics:

  • Product Types: Eflapegrastim, Filgrastim, Lipegfilgrastim, Pegfilgrastim
  • Therapies: Prophylaxis, Treatment
  • Route of Administration: Intravenous Injection, Subcutaneous Injection
  • End Users: Clinics, Home Care, Hospitals
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Treatment Settings: Inpatient, Outpatient
  • Patient Groups: Adult, Geriatric, Pediatric
  • Dosage Strengths: 5 mcg/kg, 6 mg
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (selected European, Middle Eastern, and African countries), Asia-Pacific (China, India, Japan, Australia, South Korea, and others)
  • Companies Profiled: Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Pfizer Inc., Viatris Inc., Biocon Ltd., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd.

Chemotherapy Induced Neutropenia Market: Key Takeaways

  • Neutropenia management is increasingly shaped by the uptake of long-acting and biosimilar products, which offer dosing flexibility and support outpatient care delivery.
  • Expansion of digital monitoring and real-world evidence initiatives allows for personalized prophylactic regimens and strengthens value-based contracting with payers.
  • Emerging trends include partnerships to boost regional manufacturing resilience, especially in response to supply volatility and cost inflations driven by regulatory or geopolitical shifts.
  • Real-time risk stratification using point-of-care technologies supports more precise patient identification, reducing the clinical and economic impact of neutropenic events.
  • Adoption of risk-adjusted dosing and patient support services is helping organizations differentiate their offerings and improve adherence in diverse populations.

Tariff Impact: Navigating Policy Shifts and Supply Chain Efficiency

Recent United States tariff adjustments on imported active pharmaceutical ingredients and finished dosage forms have introduced cost pressures throughout the neutropenia therapeutic supply chain. Pharmaceutical organizations are responding by evaluating onshore production, establishing dual sourcing, and engaging in customs collaborations. These measures aim to secure continuity of supply, preserve affordability, and ensure consistent patient access amidst policy volatility.

Methodology & Data Sources

The research employs a mixed-methods framework, blending qualitative interviews with oncology specialists and payers, and comprehensive secondary data analysis. Sources include peer-reviewed medical literature, clinical trial registries, company filings, expert roundtables, and external subject matter peer review. All findings are validated for clinical relevance, data integrity, and compliance with research standards, ensuring actionable insights for stakeholders.

Why This Report Matters

  • Enables informed strategic planning by providing multidimensional insights into trends, segmentation, and innovation in the chemotherapy induced neutropenia market.
  • Highlights the operational and regulatory factors affecting access, supporting proactive risk management and market adaptation.
  • Delivers actionable recommendations for product development, distribution strategies, and patient-centric service delivery.

Conclusion

The chemotherapy induced neutropenia market is marked by innovation, evolving policy, and shifting regional dynamics. This report equips decision-makers with the clarity to guide investments, partnerships, and operational strategies for sustained success and improved patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of long-acting pegfilgrastim biosimilars improving prophylaxis access and affordability for diverse oncology populations
5.2. Integration of AI-driven risk stratification tools for personalized neutropenia prevention and treatment planning in clinical settings
5.3. Adoption of oral myeloid growth factors to enhance patient convenience and adherence in community oncology practices
5.4. Rising emphasis on real-world evidence generation to demonstrate cost-effectiveness and outcomes of neutropenia interventions
5.5. Growth of telehealth-supported neutropenia management programs for remote monitoring and early intervention in rural patient cohorts
5.6. Emergence of value-based reimbursement models linking neutropenia treatment outcomes to payer contracting and pricing strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chemotherapy Induced Neutropenia Market, by Product Type
8.1. Introduction
8.2. Eflapegrastim
8.3. Filgrastim
8.4. Lipegfilgrastim
8.5. Pegfilgrastim
9. Chemotherapy Induced Neutropenia Market, by Therapy
9.1. Introduction
9.2. Prophylaxis
9.3. Treatment
10. Chemotherapy Induced Neutropenia Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous Injection
10.3. Subcutaneous Injection
11. Chemotherapy Induced Neutropenia Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Home Care
11.4. Hospital
12. Chemotherapy Induced Neutropenia Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Chemotherapy Induced Neutropenia Market, by Treatment Setting
13.1. Introduction
13.2. Inpatient
13.3. Outpatient
14. Chemotherapy Induced Neutropenia Market, by Patient Group
14.1. Introduction
14.2. Adult
14.3. Geriatric
14.4. Pediatric
15. Chemotherapy Induced Neutropenia Market, by Dosage Strength
15.1. Introduction
15.2. 5 Mcg/Kg
15.3. 6 Mg
16. Americas Chemotherapy Induced Neutropenia Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Chemotherapy Induced Neutropenia Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Chemotherapy Induced Neutropenia Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Amgen Inc.
19.3.2. Teva Pharmaceutical Industries Ltd.
19.3.3. Sandoz International GmbH
19.3.4. Pfizer Inc.
19.3.5. Viatris Inc.
19.3.6. Biocon Ltd.
19.3.7. Fresenius Kabi AG
19.3.8. Intas Pharmaceuticals Ltd.
19.3.9. Cipla Ltd.
19.3.10. Lupin Ltd.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET: RESEARCHAI
FIGURE 32. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET: RESEARCHSTATISTICS
FIGURE 33. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET: RESEARCHCONTACTS
FIGURE 34. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 106. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 107. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 114. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 115. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 116. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 117. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 118. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 119. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 130. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 131. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 132. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 133. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 134. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 201. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 204. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 205. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 212. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 213. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 214. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 215. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 216. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 217. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 220. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 221. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 228. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 229. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 230. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 231. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 232. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 249. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 252. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 253. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 260. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 261. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 262. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 263. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 264. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 265. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 268. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 269. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 276. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 277. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 278. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 279. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 280. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 297. SAUD

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Chemotherapy Induced Neutropenia market report include:
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Viatris Inc.
  • Biocon Ltd.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Lupin Ltd.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.87 Billion
Compound Annual Growth Rate4.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From
Filgrastim & Biosimilars Market by Product Type (Biosimilar Filgrastim, Originator Filgrastim), Application (Chemotherapy Induced Neutropenia, Severe Chronic Neutropenia, Stem Cell Mobilization), End User, Distribution Channel, Dosage Form, Strength - Global Forecast 2025-2030 - Product Image

Filgrastim & Biosimilars Market by Product Type (Biosimilar Filgrastim, Originator Filgrastim), Application (Chemotherapy Induced Neutropenia, Severe Chronic Neutropenia, Stem Cell Mobilization), End User, Distribution Channel, Dosage Form, Strength - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025 - Product Image

Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Pegfilgrastim Market by Application (Chemotherapy-Induced Neutropenia, Peripheral Blood Stem Cell Mobilization), Product Type (On-Body Injector, Prefilled Pen, Prefilled Syringe), Origin, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Pegfilgrastim Market by Application (Chemotherapy-Induced Neutropenia, Peripheral Blood Stem Cell Mobilization), Product Type (On-Body Injector, Prefilled Pen, Prefilled Syringe), Origin, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From

About the Chemotherapy Induced Neutropenia Market

In the context of healthcare services, the chemotherapy-induced neutropenia (CIN) market encompasses the range of medical treatments, products, and services used to prevent and manage neutropenia, a common side effect of chemotherapy where a patient's neutrophil count becomes abnormally low, increasing the risk of infection. The market includes pharmaceuticals such as colony-stimulating factors (CSFs), which stimulate the bone marrow to produce more white blood cells, antibiotics for the prevention and treatment of infections, and diagnostic services that monitor neutrophil counts and infection markers. Healthcare service providers such as hospitals, specialty clinics, and oncology centers play a crucial role in administering these treatments and monitoring patient health outcomes. Research and development efforts in this market aim to deliver more efficacious and safer therapies, with a focus on personalized medicine approaches that tailor treatment to individual patient needs and genetic profiles. Companies operating within the CIN market span a variety of pharmaceutical manufacturers and biotechnology firms. Some notable players include Amgen, which produces Neupogen and Neulasta, drugs that are commonly used to treat neutropenia, and Pfizer, which offers a biosimilar to Neulasta called Nivestym. Other companies involved in the production of treatments for CIN include Teva Pharmaceutical Industries, Novartis, and Mylan, which offer generic and biosimilar versions of CSFs and supportive care medications essential for managing neutropenia in chemotherapy patients. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.